OncoTherapy Science, Inc.

4564

JP3202150003

Biotechnology & Medical Research

Delayed Japan Exchange Other stock markets 06:56:49 22/05/2024 BST			5-day change	1st Jan Change
16 ^JPY	0.00%		0.00%	-30.43%

04-29	Poland's Tusk calls prosecutor over potential Orlen scandal	RE
04-22	OncoTherapy Science, Inc. cancelled the transaction announced on April 5, 2024	CI

OncoTherapy Science, Inc. announced that it has received ¥12.013 million in funding from Daiwa Securities Group Inc.

January 14, 2019

On January 15, 2018, OncoTherapy Science, Inc. (TSE:4564) closed the transaction.

Latest news about OncoTherapy Science, Inc.

Poland's Tusk calls prosecutor over potential Orlen scandal	04-29	RE
OncoTherapy Science, Inc. cancelled the transaction announced on April 5, 2024	04-21	CI
OncoTherapy Science, Inc. announced that it expects to receive ¥3.78 million in funding from Long Corridor Asset Management Limited and another investor	04-04	CI
OncoTherapy Science, Inc.(TSE:4564) dropped from S&P Global BMI Index	18/09/23	CI
OncoTherapy Science, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	12/05/23	CI
OncoTherapy Science, Inc. announced that it has received ¥95.95 million in funding	09/04/23	CI
OncoTherapy Science, Inc. announced that it expects to receive ¥95.95 million in funding	23/03/23	CI
OncoTherapy Science, Inc. announced that it has received ¥12.25 million in funding from Daiwa Securities Co., Ltd., Investment Arm	27/04/21	CI
OncoTherapy Science, Inc. announced that it expects to receive ¥12.25 million in funding from Daiwa Securities Co., Ltd., Investment Arm	11/04/21	CI
OncoTherapy Science, Inc. announced that it has received ¥12.013 million in funding from Daiwa Securities Group Inc.	14/01/19	CI
OncoTherapy Science, Inc. announced that it expects to receive ¥12.013 million in funding from Daiwa Securities Group Inc.	25/12/18	CI
Oncotherapy Science, Inc. and Theragen Etex Co.,Ltd., to Form Joint Venture Company	14/07/17	CI
OncoTherapy Science, Inc.(TSE:4564) added to Russell Global Index	29/06/15	CI
OncoTherapy Science, Inc. Signs Licensing Agreement with Societe d'Exploitation de Produits pour les Industries Chimiques S.A	30/07/13	CI
Shionogi & Co. Signs Agreement with OncoTherapy Science Inc. for Cancer Peptide Vaccines	01/04/12	CI

Chart OncoTherapy Science, Inc.

Duration

Period

More charts

OncoTherapy Science, Inc. is a Japan-based company mainly engaged in the development of drugs. The Company is involved in the development of low molecular drugs, antibody drugs and other drugs, as well as the provision and clinical development of medical candidate substances. The Company operates its business in cooperation with universities and other corporations. The Company provides its licenses to pharmaceutical manufacturers. The Company also involves in T Cell Receptor(TCR) analysis business.

Sector

Biotechnology & Medical Research

Calendar

01/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
ONCOTHERAPY SCIENCE, INC.	-30.43%	22.92M
VERTEX PHARMACEUTICALS INCORPORATED	+8.63%	114B
REGENERON PHARMACEUTICALS, INC.	+13.17%	107B
BIONTECH SE	-12.76%	22.22B
ARGENX SE	-3.99%	21.28B
BEIGENE, LTD.	-7.19%	17.51B
WUXI APPTEC CO., LTD.	-39.93%	17.17B
NEUROCRINE BIOSCIENCES, INC.	+6.67%	14.14B
SAREPTA THERAPEUTICS, INC.	+33.90%	12.2B
LEGEND BIOTECH CORPORATION	-28.60%	7.83B

Bio Therapeutic Drugs